Targeted therapies in thyroid cancer

Targeted Oncology

Volumn 4, Issue 4, 2009, Pages 275-285

  Capdevila, Jaume ^a   Perez Garcia, Jose ^a   Obiols, Gabriel ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Axitinib; Differentiated thyroid cancer; Medullary thyroid cancer; Motesanib; Sorafenib; Sunitinib; Targeted therapy; Thalidomide; Vandetanib

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; DEPSIPEPTIDE; GEFITINIB; JNJ 26854165; LENALIDOMIDE; LEVOTHYROXINE; MANUMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOTESANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN INHIBITOR; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; RAF PROTEIN; RAS PROTEIN; ROMIDEPSIN; ROSIGLITAZONE; SORAFENIB; SUNITINIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; XL 184;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD TOXICITY; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; ENZYME INHIBITION; ERYTHEMA; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOCYTOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; QT PROLONGATION; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH HEMORRHAGE; STOMACH ULCER; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TRACHEOESOPHAGEAL FISTULA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANIMALS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENES, RAS; HUMANS; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RATS; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72449177822     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-009-0124-y     Document Type: Review

References (67)

1. L Davies HG Welch 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 18 2164 2167 10.1001/jama.295.18.2164 1:CAS:528:DC%2BD28XksV2gtLg%3D 16684987
2. A Jemal R Siegel E Ward, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387
3. SA Hundahl ID Fleming AM Fremgen HR Menck 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 Cancer 83 12 2638 2648 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID- CNCR31>3.0.CO;2-1 1:STN:280:DyaK1M%2FovFylug%3D%3D 9874472 (Pubitemid 29019586)
4. Chan JKC, Hirokawa M, Evans H et al (2004) Tumours of the thyroid and parathyroid: follicular adenoma. WHO classification of tumours: pathology, genetics of tumours of endocrine organs. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO classification of tumours: pathology, genetics of tumours of endocrine organs. IARC, Lyon, pp 98-103
5. EL Mazzaferri SM Jhiang 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer Am J Med 97 5 418 428 10.1016/0002-9343(94)90321-2 1:STN:280:DyaK2M%2FmvVSgtA%3D%3D 7977430 (Pubitemid 24345593)
6. JP Shah TR Loree D Dharker, et al. 1992 Prognostic factors in differentiated carcinoma of the thyroid gland Am J Surg 164 6 658 661 10.1016/S0002-9610(05)80729-9 1:STN:280:DyaK3s%2FpvVektw%3D%3D 1463119
7. MJ Schlumberger 1998 Papillary and follicular thyroid carcinoma N Engl J Med 338 5 297 306 10.1056/NEJM199801293380506 1:STN:280:DyaK1c%2Fpt1SktA%3D%3D 9445411 (Pubitemid 28065257)
8. HR Maxon SR Thomas VS Hertzberg, et al. 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer N Engl J Med 309 16 937 941 1:STN:280:DyaL2c%2Fhtl2nug%3D%3D 6621620
9. C Durante N Haddy E Baudin, et al. 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 91 8 2892 2899 10.1210/jc.2005-2838 1:CAS:528:DC%2BD28XosFGhs70%3D 16684830 (Pubitemid 44271732)
10. K Shimaoka DA Schoenfeld WD DeWys RH Creech R DeConti 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 56 9 2155 2160 10.1002/1097-0142(19851101)56: 9<2155::AID-CNCR2820560903>3.0.CO;2-E 1:STN:280:DyaL28%2FislOjtw%3D%3D 3902203 (Pubitemid 16236586)
11. SD Williams R Birch LH Einhorn 1986 Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial Cancer Treat Rep 70 3 405 407 1:STN:280:DyaL287mtFCltg%3D%3D 3955552 (Pubitemid 16130224)
12. D Shibru KW Chung E Kebebew 2008 Recent developments in the clinical application of thyroid cancer biomarkers Curr Opin Oncol 20 1 13 18 10.1097/CCO.0b013e3282f27e49 1:CAS:528:DC%2BD2sXhtlGns7zO 18043251 (Pubitemid 350190976)
13. MN Nikiforova YE Nikiforov 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Rev Mol Diagn 8 1 83 95 10.1586/14737159.8.1.83 1:CAS:528:DC%2BD2sXhsVCgtr7J 18088233
14. ET Kimura MN Nikiforova Z Zhu JA Knauf YE Nikiforov JA Fagin 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 7 1454 1457 1:CAS:528:DC%2BD3sXisFaisLs%3D 12670889
15. N Motoi A Sakamoto T Yamochi H Horiuchi T Motoi R Machinami 2000 Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin Pathol Res Pract 196 1 1 7 1:CAS:528:DC%2BD3cXhs1arsLg%3D 10674266
16. MN Nikiforova ET Kimura M Gandhi, et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas J Clin Endocrinol Metab 88 11 5399 5404 10.1210/jc.2003-030838 1:CAS:528:DC%2BD3sXptVyntrs%3D 14602780 (Pubitemid 37452745)
17. A Casamassimi MG Miano A Porcellini, et al. 1998 p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation Cancer Res 58 13 2888 2894 1:CAS:528:DyaK1cXksFCqtLg%3D 9661907
18. TG Kroll P Sarraf L Pecciarini, et al. 2000 PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma Science 289 5483 1357 1360 10.1126/science.289.5483.1357 1:CAS:528:DC%2BD3cXmt1amsbw%3D 10958784 (Pubitemid 30656054)
19. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 10 795 803 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D 12360282 (Pubitemid 37328914)
20. RK Jain 2003 Molecular regulation of vessel maturation Nat Med 9 6 685 693 10.1038/nm0603-685 1:CAS:528:DC%2BD3sXktFOnurw%3D 12778167 (Pubitemid 36749217)
21. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 3 5 1011 1027
22. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 21 4368 4380 10.1200/JCO.2002.10.088 1:CAS:528:DC%2BD38Xpt1CjtL0%3D 12409337 (Pubitemid 35266299)
23. NG de la Torre I Buley JA Wass HE Turner 2006 Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour 13 3 931 944
24. XM Yu CY Lo WF Chan KY Lam P Leung JM Luk 2005 Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases Clin Cancer Res 11 22 8063 8069 10.1158/1078-0432.CCR-05-0646 1:CAS:528:DC%2BD2MXht1entr%2FI 16299237 (Pubitemid 41698749)
25. G Viglietto D Maglione M Rambaldi, et al. 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines Oncogene 11 8 1569 1579 1:CAS:528:DyaK2MXptVymt7Y%3D 7478581
26. SM Wilhelm C Carter L Tang, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 7099 7109 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D 15466206 (Pubitemid 39331023)
27. F Carlomagno S Anaganti T Guida, et al. 2006 BAY 43-9006 inhibition of oncogenic RET mutants J Natl Cancer Inst 98 5 326 334 1:CAS:528: DC%2BD28XitVyjsrs%3D 16507829
28. MJ Ratain KT Flaherty WM Stadler, et al. 2004 Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) Proc Am Soc Clin Oncol 22 14S 4501
29. V Gupta-Abramson AB Troxel A Nellore, et al. 2008 Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 29 4714 4719 10.1200/JCO.2008.16.3279 1:CAS:528:DC%2BD1cXhtlSqsb7M 18541894
30. RT Kloos MD Ringel MV Knopp, et al. 2009 Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 10 1675 1684 10.1200/JCO.2008.18.2717 1:CAS:528:DC%2BD1MXltVOht7g%3D 19255327
31. CW Reuter MA Morgan L Bergmann 2000 Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96 5 1655 1669 1:CAS:528:DC%2BD3cXmt1Omt7g%3D 10961860
32. SC Yeung G Xu J Pan M Christgen A Bamiagis 2000 Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells Cancer Res 60 3 650 656 1:CAS:528:DC%2BD3cXht1GmtLc%3D 10676649
33. DS Hong L Camacho C Ng, et al. 2007 Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers Proc Am Soc Clin Oncol 25 18S 3549
34. G Pearson F Robinson T Beers Gibson, et al. 2001 Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr Rev 22 2 153 183 10.1210/er.22.2.153 1:CAS:528:DC%2BD3MXjsFSntL4%3D 11294822 (Pubitemid 32458157)
35. R Agarwal U Banerji DR Camidge, et al. 2008 The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): a phase I trial in patients (pts) with advanced cancer Proc Am Soc Clin Oncol 26 20S 3535
36. A Polverino A Coxon C Starnes, et al. 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 66 17 8715 8721 10.1158/0008-5472.CAN-05-4665 1:CAS:528:DC%2BD28XovF2hs7w%3D 16951187 (Pubitemid 44449188)
37. SI Sherman LJ Wirth JP Droz, et al. 2008 Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 359 1 31 42 10.1056/NEJMoa075853 1:CAS:528:DC%2BD1cXotFSisL8%3D 18596272 (Pubitemid 351931094)
38. D Hu-Lowe M Hallin R Feeley, et al. 2002 Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736 Proc Am Assoc Cancer Res 43 5357
39. HS Rugo RS Herbst G Liu, et al. 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 24 5474 5483 10.1200/JCO.2005.04.192 1:CAS:528:DC%2BD2MXhtVersr7F 16027439 (Pubitemid 46300140)
40. EE Cohen LS Rosen EE Vokes, et al. 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 29 4708 4713 10.1200/JCO.2007.15.9566 1:CAS:528: DC%2BD1cXhtlSqsLfE 18541897
41. LQ Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 7 884 896 10.1200/JCO.2006.06.3602 1:CAS:528: DC%2BD2sXjvVKmtLY%3D 17327610 (Pubitemid 350002890)
42. CD Britten F Kabbinavar JR Hecht, et al. 2008 A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period Cancer Chemother Pharmacol 61 3 515 524 10.1007/s00280-007- 0498-4 1:CAS:528:DC%2BD1cXisl2ks7g%3D 17505827 (Pubitemid 350275988)
43. A Ravaud C de la Fouchardière F Courbon, et al. 2008 Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial Proc Am Soc Clin Oncol 26 20S 6058
44. EE Cohen BM Needles KJ Cullen, et al. 2008 Phase 2 study of sunitinib in refractory thyroid cancer Proc Am Soc Clin Oncol 26 20S 6025
45. B Goulart L Carr RG Martins, et al. 2008 Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) Proc Am Soc Clin Oncol 26 20S 6062
46. P Wolter C Stefan B Decallonne, et al. 2008 Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) Proc Am Soc Clin Oncol 26 20S 5126
47. RS Herbst JV Heymach MS O'Reilly A Onn AJ Ryan 2007 Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis Expert Opin Investig Drugs 16 2 239 249 10.1517/13543784.16.2.239 1:CAS:528:DC%2BD2sXotVajtA%3D%3D 17243944 (Pubitemid 46206638)
48. SA Wells JE Gosnell RF Gagel, et al. 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial Proc Am Soc Clin Oncol 25 18S 6018
49. RI Haddad AD Krebs J Vasselli LG Paz-Ares B Robinson 2008 A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer Proc Am Soc Clin Oncol 26 20S 6024
50. K Masago R Asato S Fujita, et al. 2009 Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma Int J Cancer 124 11 2744 2749 10.1002/ijc.24250 1:CAS:528:DC%2BD1MXltlegu7k%3D 19253367
51. M Croyle N Akeno JA Knauf, et al. 2008 RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR Cancer Res 68 11 4183 4191 10.1158/0008-5472.CAN-08-0413 1:CAS:528:DC%2BD1cXmsFKmtb4%3D 18519677
52. NA Pennell GH Daniels RI Haddad, et al. 2008 A phase II study of gefitinib in patients with advanced thyroid cancer Thyroid 18 3 317 323 10.1089/thy.2007.0120 1:CAS:528:DC%2BD1cXjt1Gju70%3D 17985985
53. R Salgia S Sherman DS Hong, et al. 2008 A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) Proc Am Soc Clin Oncol 26 20S 3522
54. JP Eder E Heath L Appleman, et al. 2007 Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors Proc Am Soc Clin Oncol 25 18S 3526
55. AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G Kaplan 1993 Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 177 1675 1680 10.1084/jem.177.6.1675 1:CAS:528:DyaK3sXitVCqsrY%3D 8496685
56. RJ D'Amato MS Loughnan E Flynn J Folkman 1994 Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 9 4082 4085 10.1073/pnas.91.9.4082 7513432
57. AJ Bauer R Terrell NK Doniparthi, et al. 2002 Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice Thyroid 12 11 953 961 10.1089/105072502320908286 1:CAS:528:DC%2BD3sXktlaktQ%3D%3D 12490072
58. KB Ain C Lee KD Williams 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas Thyroid 17 7 663 670 10.1089/thy.2006.0289 1:CAS:528:DC%2BD2sXptVWqtL4%3D 17696837 (Pubitemid 47311556)
59. S Vallet A Palumbo N Raje M Boccadoro KC Anderson 2008 Thalidomide and lenalidomide: mechanism-based potential drug combinations Leuk Lymphoma 49 7 1238 1245 10.1080/10428190802005191 1:CAS:528:DC%2BD1cXot1Kltro%3D 18452080 (Pubitemid 352015786)
60. KB Ain C Lee KM Holbrook JM Dziba KD Williams 2008 Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results Proc Am Soc Clin Oncol 26 20S 6027
61. J Chen V Marechal AJ Levine 1993 Mapping of the p53 and mdm-2 interaction domains Mol Cell Biol 13 4107 4114 1:CAS:528:DyaK3sXlsFehu74%3D 7686617
62. A Hoos A Stojadinovic B Singh, et al. 2002 Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays Am J Pathol 160 1 175 183 1:CAS:528: DC%2BD38XnvFehtQ%3D%3D 11786411
63. Tabernero J, Schöffski P, Dirix L et al (2008) Phase I study to determine the safety, pharmacology, and pharmacodynamics of JNJ-26854165 in subjects with advanced stage and/or refractory solid tumors. EORTC-NCI-AACR Annual Meeting 2008, oral abstract 1592
64. R Piekarz V Luchenko D Draper, et al. 2008 Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers Proc Am Soc Clin Oncol 26 20S 3571
65. E Kebebew M Peng E Reiff, et al. 2006 A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 140 6 960 966 10.1016/j.surg.2006.07.038 17188145 (Pubitemid 44937397)
66. Y Zhang S Jia Y Liu, et al. 2007 A clinical study of all-trans-retinoid- induced differentiation therapy of advanced thyroid cancer Nucl Med Commun 28 4 251 255 10.1097/MNM.0b013e3280708ebf 17325586 (Pubitemid 46673200)
67. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 228 247 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 19097774